The growing field of immunotherapy relies heavily on recombinant mediator technology, and a detailed understanding of individual profiles is essential for fine-tuning experimental design and therapeutic efficacy. Specifically, examining the properties of recombinant IL-1A, IL-1B, IL-2, and IL-3 highlights significant differences in their molecular